Macrophage Pharma appoints Dr Michael Moore as chairman
11 April 2018 -

Macrophage Pharma has appointed Dr Michael Moore as non-executive chairman with immediate effect, the private company announced on Wednesday.

Dr Moore brings extensive drug discovery and development expertise. He currently serves as a non-executive director for several private and public bioscience companies, including Mission Therapeutics where he was founder chairman, Trillium Therapeutics Inc (TSE: TRIL), and Mironid Ltd. He is also chairman of Chronos Therapeutics and was the founder chairman for PsiOxus Therapeutics.

Prior to that, Dr Moore held the role of CEO at Piramed, which was acquired by Roche (VTX: ROG) in 2008, and was the research director and CSO of Xenova Group plc.

Before joining the UK biotechnology sector, Dr Moore, who is a fellowship of the Royal College of Pathologists, had a long career in academic research, most notably at the Paterson Institute for Cancer Research and the University of Manchester where he was Honorary Reader in immunology and oncology. He also served as the chairman of Cancer Research UK's drug discovery committee.

Macrophage Pharma is focused on the discovery and development of next-generation small molecules to modulate immune responses in order to combat cancer, as well as other diseases.